Tom Powles, Head of Solid Tumor Research at Barts Cancer Institute, shared on X:
“Ivonescimab (with chemo) has been rejected by FDA in EGFRm TKI refractory lung cancer.
The trial achieved impressive PFS but not OS (with some subgroup inconsistency).
We see PFS achieve approvals without OS in other tumours including all 3 GU cancers. It’s not always easy to predict the future in terms of results or regulatory approvals, but the class of drug seems broadly active.
VEFF/PD1s are in R3 trials in bladder cancer with EV.”
You can also read: